SIGLEC8: A Potential Drug Target and Biomarker (G27181)

Target Name: SIGLEC8

NCBI ID: G27181

SIGLEC8

SIGLEC8: A Potential Drug Target and Biomarker

Siglec8, short for signal transducer and gene encoder 8, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for researchers to study and develop new treatments.

The protein SIGLEC8 is composed of 251 amino acids and has a molecular weight of 31 kDa. It is a type of transmembrane protein that is expressed in various tissues and cells throughout the body, including the brain, pancreas, and gastrointestinal tract. SIGLEC8 is involved in several signaling pathways, including the TGF-β pathway, which plays a crucial role in cell growth, differentiation, and survival.

One of the key functions of SIGLEC8 is its role in the TGF-β pathway. This pathway is involved in the regulation of cell growth, cell-cell adhesion, and the development of tissues and organs. SIGLEC8 has been shown to play a negative role in the TGF-β pathway, by regulating the activity of the transcription factor SMAD2. This transcription factor is responsible for transcription of pre-mRNA, which is the first step in the regulation of gene expression.

SIGLEC8 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis, such as cell migration and the regulation of ion and water transport.

SIGLEC8 is also involved in the regulation of inflammation, which is a critical aspect of many diseases, including cancer and neurodegenerative diseases. SIGLEC8 has been shown to play a role in the regulation of immune cell function, by regulating the production of pro-inflammatory cytokines.

SIGLEC8 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been shown to be elevated in various tissues and cells that are affected by these diseases, which could make it an attractive target for diagnostic tests and potential therapies.

In conclusion, SIGLEC8 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and function make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of SIGLEC8 in these diseases and to develop new treatments.

Protein Name: Sialic Acid Binding Ig Like Lectin 8

Functions: Putative adhesion molecule that mediates sialic-acid dependent binding to red blood cells (PubMed:10856141, PubMed:10625619). Preferentially binds to alpha-2,3-linked sialic acid. Also binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface (PubMed:10625619). Recognizes simultaneously epitopes having a terminal N-acetylneuraminic acid (sialic acid) and an underlying 6-O-sulfated galactose. Preferentially binds to Gal-6-sulfated sialyl-Lewis X glycan epitopes (PubMed:27357658)

The "SIGLEC8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLEC8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets